文献速递神经肿瘤

影像组合提高弥漫性胶质瘤浸润检测的诊断准确性研究

Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study.
PubMed 文献 · Neuro Oncol · 2020-01-01

该研究纳入20例新诊断弥漫性胶质瘤成人患者,术前标准化影像与多区域立体定向活检共定位,用ROC分析评估影像组合检测肿瘤浸润的准确性。在强化胶质瘤中,ADC联合[18F]FET PET检测肿瘤优于T1G MRI和单独[18F]FET PET;在非强化胶质瘤中,无影像组合显著优于标准MRI。

要点

  • 强化胶质瘤中ADC联合[18F]FET PET检测浸润优于T1G MRI和单独PET。
  • 非强化胶质瘤中无影像组合显著优于标准MRI。
  • FLAIR加权MRI在非强化胶质瘤中AUC高于[18F]FET PET。

核心结论

  • 在强化胶质瘤中,ADC联合[18F]FET PET检测肿瘤浸润优于标准MRI和单独[18F]FET PET。
  • 在非强化胶质瘤中,无影像组合检测肿瘤显著优于标准MRI。

研究设计与样本

  • 纳入20例连续成人新诊断弥漫性胶质瘤患者,其中非强化胶质瘤9例、强化胶质瘤11例。
  • 术前标准化影像与多区域立体定向活检共定位,由2名神经病理学家评估肿瘤存在。
  • 采用受试者工作特征分析确定诊断准确性。

主要发现

  • 共获得174个活检样本,其中129个含肿瘤(非强化胶质瘤50个,强化胶质瘤79个)。
  • 强化胶质瘤中,ADC联合[18F]FET PET的AUC为0.89(95%CI 0.79‒0.99),优于T1G MRI的0.56(0.39‒0.72;P < 0.001)和[18F]FET PET的0.76(0.66‒0.86;P = 0.001)。
  • 非强化胶质瘤中,FLAIR加权MRI的AUC为0.81(0.65-0.98),高于[18F]FET PET的0.69(0.56-0.81;P = 0.019)。

临床怎么用

  • 对于强化胶质瘤,可考虑联合ADC与[18F]FET PET以更准确检测肿瘤浸润,可能有助于指导局部治疗。
  • 对于非强化胶质瘤,标准MRI(如FLAIR)仍是检测肿瘤浸润的主要影像手段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgical resection and irradiation of diffuse glioma are guided by standard MRI: T2/fluid attenuated inversion recovery (FLAIR)-weighted MRI for non-enhancing and T1-weighted gadolinium-enhanced (T1G) MRI for enhancing gliomas. Amino acid PET has been suggested as the new standard. Imaging combinations may improve standard MRI and amino acid PET. The aim of the study was to determine the accuracy of imaging combinations to detect glioma infiltration. METHODS: We included 20 consecutive adults with newly diagnosed non-enhancing glioma (7 diffuse astrocytomas, isocitrate dehydrogenase [IDH] mutant; 1 oligodendroglioma, IDH mutant and 1p/19q codeleted; 1 glioblastoma IDH wildtype) or enhancing glioma (glioblastoma, 9 IDH wildtype and 2 IDH mutant). Standardized preoperative imaging (T1-, T2-, FLAIR-weighted, and T1G MRI, perfusion and diffusion MRI, MR spectroscopy and O-(2-[18F]-fluoroethyl)-L-tyrosine ([18F]FET) PET) was co-localized with multiregion stereotactic biopsies preceding resection. Tumor presence in the biopsies was assessed by 2 neuropathologists. Diagnostic accuracy was determined using receiver operating characteristic analysis. RESULTS: A total of 174 biopsies were obtained (63 from 9 non-enhancing and 111 from 11 enhancing gliomas), of which 129 contained tumor (50 from non-enhancing and 79 from enhancing gliomas). In enhancing gliomas, the combination of apparent diffusion coefficient (ADC) with [18F]FET PET (area under the curve [AUC], 95% CI: 0.89, 0.79‒0.99) detected tumor better than T1G MRI (0.56, 0.39‒0.72; P < 0.001) and [18F]FET PET (0.76, 0.66‒0.86; P = 0.001). In non-enhancing gliomas, no imaging combination detected tumor significantly better than standard MRI. FLAIR-weighted MRI had an AUC of 0.81 (0.65-0.98) compared with 0.69 (0.56-0.81; P = 0.019) for [18F]FET PET. CONCLUSION: Combining ADC and [18F]FET PET detects glioma infiltration better than standard MRI and [18F]FET PET in enhancing gliomas, potentially enabling better guidance of local therapy.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Verburg N, Koopman T, Yaqub MM, et al. Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study. Neuro Oncol. 2020. PMID: 31550353. doi:10.1093/neuonc/noz180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。